Skip to content
← All treatment topics

TREATMENT READING

Skin Cancer

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

55 sections
  1. Treatment Option Overview
  2. Treatment of Basal Cell Carcinoma of the Skin
  3. Treatment of Basal Cell Carcinoma of the Skin (Localized Disease)
  4. Surgical excision with margin evaluation
  5. Mohs micrographic surgery
  6. Radiation therapy
  7. Curettage and electrodesiccation
  8. Cryosurgery
  9. Photodynamic therapy
  10. Topical fluorouracil (5-FU)
  11. Imiquimod topical therapy
  12. Carbon dioxide laser
  13. Treatment of Metastatic Basal Cell Carcinoma (or Locally Advanced Disease Untreatable by Local Modalities)
  14. Hedgehog pathway inhibitors
  15. Chemotherapy
  16. Treatment of Recurrent Nonmetastatic Basal Cell Carcinoma of the Skin
  17. Treatment of Squamous Cell Carcinoma of the Skin
  18. Treatment of Squamous Cell Carcinoma of the Skin (Localized Disease)
  19. Surgical excision with margin evaluation
  20. Mohs micrographic surgery
  21. Radiation therapy
  22. Curettage and electrodesiccation
  23. Cryosurgery
  24. Treatment of SCC in situ (Bowen disease)
  25. Treatment of Metastatic Squamous Cell Carcinoma (or Advanced Disease Untreatable by Local Modalities)
  26. Immunotherapy (PD-1 inhibitors)
  27. Cemiplimab
  28. Pembrolizumab
  29. Treatment of Recurrent Nonmetastatic Squamous Cell Carcinoma of the Skin
  30. Treatment of Actinic Keratosis
  31. Certain factors affect prognosis (chance of recovery) and treatment options.
  32. Treatment depends on the type of skin cancer or other skin condition diagnosed:
  33. Basal cell carcinoma
  34. Squamous cell carcinoma
  35. Actinic keratosis
  36. Treatment Option Overview
  37. Key Points
  38. There are different types of treatment for patients with basal cell carcinoma, squamous cell carcinoma of the skin, and actinic keratosis.
  39. The following types of treatment are used:
  40. Surgery
  41. Radiation therapy
  42. Chemotherapy
  43. Photodynamic therapy
  44. Immunotherapy
  45. Targeted therapy
  46. Chemical peel
  47. Other drug therapy
  48. New types of treatment are being tested in clinical trials.
  49. Treatment for skin cancer may cause side effects.
  50. Patients may want to think about taking part in a clinical trial.
  51. Patients can enter clinical trials before, during, or after starting their cancer treatment.
  52. Follow-up tests may be needed.
  53. Treatment of Basal Cell Carcinoma
  54. Treatment of Squamous Cell Carcinoma of the Skin
  55. Treatment of Actinic Keratosis

Health professional

Treatment Option Overview

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Treatments for squamous cell carcinoma and basal cell carcinoma of the skin are described in Table 10.

Sources: Table 10

Table 10. Treatment Option Overview for Nonmelanoma Skin Cancer
Stage (American Joint Committee on Cancer Staging Criteria)Treatment Options
Basal cell carcinomaLocalized diseaseSurgical excision with margin evaluation
Mohs micrographic surgery
Radiation therapy
Curettage and electrodesiccation
Cryosurgery
Photodynamic therapy
Topical fluorouracil (5-FU)
Imiquimod topical therapy
Carbon dioxide laser
Metastatic or locally advanced disease untreatable by local modalitiesHedgehog pathway inhibitors
Recurrent nonmetastatic diseaseSurgical excision
Mohs micrographic surgery
Squamous cell carcinomaLocalized diseaseSurgical excision with margin evaluation
Mohs micrographic surgery
Radiation therapy
Curettage and electrodesiccation
Cryosurgery
Metastatic or locally advanced disease untreatable by local modalitiesImmunotherapy (PD-1 inhibitors)
Recurrent nonmetastatic diseaseSurgical excision
Mohs micrographic surgery
Radiation therapy
Actinic keratosisLocalized diseaseTopical agents
Chemical peels
Surgery
Photodynamic therapy
Laser therapy

Sources: American Joint Committee on Cancer Staging Criteria · Surgical excision with margin evaluation · Mohs micrographic surgery · Radiation therapy · Curettage and electrodesiccation · Cryosurgery · Photodynamic therapy · Topical fluorouracil (5-FU) · Imiquimod topical therapy · Carbon dioxide laser · Hedgehog pathway inhibitors · Surgical excision · Mohs micrographic surgery · Surgical excision with margin evaluation · Mohs micrographic surgery · Radiation therapy · Curettage and electrodesiccation · Cryosurgery · Immunotherapy (PD-1 inhibitors) · Surgical excision · Mohs micrographic surgery · Radiation therapy · Topical agents · Chemical peels · Surgery · Photodynamic therapy · Laser therapy

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional

Treatment of Basal Cell Carcinoma of the Skin

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

There is a wide range of approaches for treating basal cell carcinoma (BCC) of the skin, including excision, radiation therapy, cryosurgery, electrodesiccation and curettage, photodynamic or laser-beam light exposure, and topical therapies. Each of these approaches is useful in specific clinical situations. Depending on case selection, these approaches produce recurrence-free rates ranging from 85% to 95%.[1-9]

Sources: 1 · 9

A systematic review of 27 randomized controlled trials comparing various treatments for BCC has been published.[10] Eighteen of the studies were published in full, and nine were published in abstract form only. Only 19 of the 27 trials were analyzed by intention-to-treat criteria. Because the case fatality rate of BCC is so low, the primary end point of most trials is complete response and/or recurrence rate after treatment. Most of the identified studies were not of high quality and had short follow-up periods, which will lead to overestimations of tumor control; only one study had a follow-up period of as long as 4 years. A literature review of recurrence rates in case series with long-term follow-up after treatment of BCCs indicated that only 50% of recurrences occurred within the first 2 years, 66% after 3 years, and 18% after 5 years.[11] A common finding was that the 10-year recurrence rates were about double the 2-year recurrence rates.

Sources: 10 · 11

Health professional · Treatment of Basal Cell Carcinoma of the Skin

Treatment of Basal Cell Carcinoma of the Skin (Localized Disease)

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Treatment options for BCC of the skin (localized disease) include:

Surgical excision with margin evaluation.

Sources: Surgical excision with margin evaluation

Mohs micrographic surgery.

Sources: Mohs micrographic surgery

Radiation therapy.

Sources: Radiation therapy

Curettage and electrodesiccation.

Sources: Curettage and electrodesiccation

Cryosurgery.

Sources: Cryosurgery

Photodynamic therapy.

Sources: Photodynamic therapy

Topical fluorouracil (5-FU).

Sources: Topical fluorouracil (5-FU)

Imiquimod topical therapy.

Sources: Imiquimod topical therapy

Carbon dioxide laser.

Sources: Carbon dioxide laser

Health professional · Treatment of Basal Cell Carcinoma of the Skin / Treatment of Basal Cell Carcinoma of the Skin (Localized Disease)

Surgical excision with margin evaluation

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

A traditional surgical treatment, surgical excision with margin evaluation usually relies on surgical margins ranging from 3 mm to 10 mm, depending on the diameter of the tumor. Re-excision may be required if the surgical margin is found to be inadequate on permanent sectioning. In one trial, 35 of 199 primary BCCs (18%) were incompletely excised by the initial surgery and underwent a re-excision.[12] In addition, many laboratories examine only a small fraction of the total tumor margin pathologically. Therefore, the declaration of tumor-free margins can be subject to sampling error.[13]

Sources: 12 · 13

In randomized trials, excision has been compared with radiation therapy, Mohs micrographic surgery, photodynamic therapy (PDT), and cryosurgery.

Evidence (surgical excision with margin evaluation):

In a single-center trial, 360 patients with facial BCCs smaller than 4 cm in diameter were randomly assigned to undergo either surgical excision or radiation therapy (55% interstitial brachytherapy, 33% contact radiation therapy, and 12% conventional external-beam radiation therapy [EBRT]).[14][Level of evidence B1] Excisional margins, assessed by frozen section during the procedure in 91% of cases, had to be at least 2 mm, with re-excision if necessary. Thirteen patients were not treated and were dropped from the analysis.

Sources: 14 · Level of evidence B1

In a single-center trial, 360 patients with facial BCCs smaller than 4 cm in diameter were randomly assigned to undergo either surgical excision or radiation therapy (55% interstitial brachytherapy, 33% contact radiation therapy, and 12% conventional external-beam radiation therapy [EBRT]).[14][Level of evidence B1] Excisional margins, assessed by frozen section during the procedure in 91% of cases, had to be at least 2 mm, with re-excision if necessary. Thirteen patients were not treated and were dropped from the analysis.

At 4 years (mean follow-up of 41 months), the actuarial failure rates (confirmed persistent or recurrent tumor) were 0.7% in the surgery arm and 7.5% in the radiation therapy arm (P = .003).[15][Level of evidence B1]

Sources: 15 · Level of evidence B1

The cosmetic results were also rated as better after surgery by both patients and dermatologists, and also by three independent professionals. At 4 years, 87% of surgery patients rated cosmesis as good, versus 69% of radiation therapy patients.[15]

Sources: 15

In a two-center, intent-to-treat analysis, 374 patients with 408 primary facial BCCs were randomly assigned to undergo either surgical excision or Mohs micrographic surgery with at least a 3-mm margin around the visible tumor until there were no positive margins in either case.[12][Level of evidence B1]

Sources: 12 · Level of evidence B1

In a two-center, intent-to-treat analysis, 374 patients with 408 primary facial BCCs were randomly assigned to undergo either surgical excision or Mohs micrographic surgery with at least a 3-mm margin around the visible tumor until there were no positive margins in either case.[12][Level of evidence B1]

After 30 months of follow-up, the recurrence rate was 5 out of 171 tumors (3%) in the excision group and 3 out of 160 (2%) in the Mohs micrographic surgery group (absolute difference, 1%; 95% confidence interval [CI], -2.5% to +3.7%; P = .724). There was no difference in complication rates, and overall cosmetic outcomes were similar.[12][Level of evidence B1]

Sources: 12 · Level of evidence B1

Total operative costs were nearly twice as high in the Mohs group (405.79 Euros vs. 216.86 Euros; P < .001).

A multicenter randomized trial included 101 adults with previously untreated nodular skin BCCs, excluding lesions of the midface, orbital areas, and ears. Patients were treated with either excision (at least 5-mm margins) or PDT using topical methyl aminolevulinate cream (160 mg/g) followed by red-light exposure (wavelength 570–670 nm, 75 J/cm2) twice, 7 days apart.[16][Level of evidence B3] A per-protocol/per-lesion analysis was performed on the 97 patients who had an excision or at least one cycle of PDT.

Sources: 16 · Level of evidence B3

A multicenter randomized trial included 101 adults with previously untreated nodular skin BCCs, excluding lesions of the midface, orbital areas, and ears. Patients were treated with either excision (at least 5-mm margins) or PDT using topical methyl aminolevulinate cream (160 mg/g) followed by red-light exposure (wavelength 570–670 nm, 75 J/cm2) twice, 7 days apart.[16][Level of evidence B3] A per-protocol/per-lesion analysis was performed on the 97 patients who had an excision or at least one cycle of PDT.

At 3 months, the complete response (CR) rate was 98% of lesions (51 of 52) in the surgery group versus 91% of lesions (48 of 53) in the PDT group (P = .25). CR rates assessed at 12 months were 96% for the surgery group versus 83% for the PDT group (P = .15).[16][Level of evidence B3] The investigators interpreted the results as noninferiority of PDT, but the study may have been underpowered.

Sources: 16 · Level of evidence B3

Both the investigators and the patients rated the cosmetic results as either excellent or good in a higher proportion of PDT treatments at each time point of follow-up. At 12 months, patient ratings of excellent or good were 98% in the PDT group versus 84% in the surgery group (P = .03), and investigator ratings were 79% versus 38% (P = .001).

In a randomized single-center trial, 96 primary BCCs (patient number unclear) smaller than 2 cm in diameter involving the head and neck area were randomly assigned to either excision with a 3-mm safe margin or cryosurgery (i.e., curettage plus two freeze-thaw cycles by liquid nitrogen spray gun).[17][Level of evidence B3]

Sources: 17 · Level of evidence B3

In a randomized single-center trial, 96 primary BCCs (patient number unclear) smaller than 2 cm in diameter involving the head and neck area were randomly assigned to either excision with a 3-mm safe margin or cryosurgery (i.e., curettage plus two freeze-thaw cycles by liquid nitrogen spray gun).[17][Level of evidence B3]

At 1 year, there were no recurrences in the excision group versus three recurrences in the cryosurgery group (P = NS), but this is a very short follow-up time.[17][Level of evidence B3]

Sources: 17 · Level of evidence B3

Patients and five independent professionals who were blinded to the treatment arm rated the cosmetic outcomes. Their overall assessments favored excision.

Health professional · Treatment of Basal Cell Carcinoma of the Skin / Treatment of Basal Cell Carcinoma of the Skin (Localized Disease)

Mohs micrographic surgery

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Mohs micrographic surgery is a form of tumor excision that involves progressive radial sectioning and real-time examination of the resection margins until adequate uninvolved margins have been achieved, avoiding wider margins than needed. It is a specialized technique used to achieve the narrowest margins necessary to avoid tumor recurrence while maximally preserving cosmesis. The tumor is microscopically delineated, with serial radial resection, until it is completely removed as assessed with real-time frozen sections. Noncontrolled case series suggested that the disease control rates were superior to other treatment methods for BCC.[18-20] However, as noted in the Surgical excision with margin evaluation section, the disease control rate was not clearly better when it was directly compared with the disease control rate for surgical excision of facial BCCs in a randomized trial of primary BCCs.[12]

Sources: 18 · 20 · Surgical excision with margin evaluation · 12

This surgery is best suited to the management of tumors that have recurred after initial incision or of tumors in cosmetically sensitive areas (e.g., eyelid periorbital area, nasolabial fold, nose-cheek angle, posterior cheek sulcus, pinna, ear canal, forehead, scalp, fingers, and genitalia).[19,21] It is also used to treat tumors with poorly defined clinical borders.

Sources: 19 · 21

Health professional · Treatment of Basal Cell Carcinoma of the Skin / Treatment of Basal Cell Carcinoma of the Skin (Localized Disease)

Radiation therapy

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Radiation therapy is particularly useful in the management of patients with primary lesions that would otherwise require difficult or extensive surgery (e.g., lesions on the nose or ears).[22] Radiation therapy eliminates the need for skin grafting when surgery would result in an extensive defect. Cosmetic results are generally good, with a small amount of hypopigmentation or telangiectasia in the treatment port. Radiation therapy can also be used for lesions that recur after a primary surgical approach.[23]

Sources: 22 · 23

Radiation therapy is avoided in patients with conditions that predispose them to radiation-induced cancers, such as xeroderma pigmentosum or basal cell nevus syndrome.

Evidence (radiation therapy):

As noted above, radiation therapy has been compared with excision in a randomized trial that showed better response and cosmesis associated with surgery.[14,15][Level of evidence B1]

Sources: 14 · 15 · Level of evidence B1

In a single-center trial, 93 patients with BCC were randomly assigned to receive either EBRT (130 kV x-rays, dosimetry depending on lesion size) or cryotherapy (two freeze-thaw cycles with liquid nitrogen by spray gun). Patients with lesions on the nose or ear were excluded because the investigators felt that EBRT is the treatment of choice for tumors in these locations.[24][Level of evidence B3]

Sources: 24 · Level of evidence B3

In a single-center trial, 93 patients with BCC were randomly assigned to receive either EBRT (130 kV x-rays, dosimetry depending on lesion size) or cryotherapy (two freeze-thaw cycles with liquid nitrogen by spray gun). Patients with lesions on the nose or ear were excluded because the investigators felt that EBRT is the treatment of choice for tumors in these locations.[24][Level of evidence B3]

Radiation was superior to cryotherapy in local control at 2 years.

By 1 year, the recurrence rate was 4% in the radiation arm and 39% in the cryotherapy arm in a per-protocol analysis. The investigators did not perform a statistical analysis, but the authors of a systematic literature review calculated a relative risk of 0.11 in favor of radiation (95% CI, 0.03–0.43).[10][Level of evidence B3]

Sources: 10 · Level of evidence B3

Health professional · Treatment of Basal Cell Carcinoma of the Skin / Treatment of Basal Cell Carcinoma of the Skin (Localized Disease)

Curettage and electrodesiccation

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Curettage and electrodesiccation is a widely employed method for removing primary BCCs, especially superficial lesions of the neck, trunk, and extremities that are considered to be at low risk of recurrence. A sharp curette is used to scrape the tumor down to its base, followed by electrodesiccation of the lesion base. Although curettage and electrodesiccation is a quick method for destroying the tumor, the adequacy of treatment cannot be assessed immediately because the surgeon cannot visually detect the depth of microscopic tumor invasion. This procedure is also sometimes called electrosurgery.

Evidence (curettage and electrodesiccation):

A Cochrane Collaboration systematic review found no randomized trials comparing this treatment method with other approaches.[10]

Sources: 10

In a large, single-center case series of 2,314 previously untreated BCCs managed at a major skin cancer unit, the 5-year recurrence rate of BCCs of the neck, trunk, and extremities after curettage and electrodesiccation was 3.3%. However, rates increased substantially for tumors larger than 6 mm in diameter at other anatomical sites.[25][Level of evidence C2]

Sources: 25 · Level of evidence C2

Health professional · Treatment of Basal Cell Carcinoma of the Skin / Treatment of Basal Cell Carcinoma of the Skin (Localized Disease)

Cryosurgery

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Cryosurgery may be considered for patients with small, clinically well-defined primary tumors.[26-28] It is infrequently used for the management of BCC, but cryosurgery may be useful for patients with medical conditions that preclude other types of surgery.[8,29-35] Contraindications for cryosurgery include:

Sources: 26 · 28 · 8 · 29 · 35

Abnormal cold tolerance.

Cryoglobulinemia or cryofibrinogenemia.

Raynaud disease (in the case of lesions on the hands and feet).

Platelet deficiency disorders.

Tumors of the scalp, ala nasi, nasolabial fold, tragus, postauricular sulcus, free eyelid margin, upper lip vermillion border, and lower legs.

Tumors near nerves.

Caution should also be used before treating nodular ulcerative neoplasia more than 3 cm in diameter, carcinomas fixed to the underlying bone or cartilage, tumors situated on the lateral margins of the fingers and at the ulnar fossa of the elbow, or recurrent carcinomas following surgical excision. Permanent pigment loss at the treatment site is unavoidable, so the treatment is not well suited to patients with dark skin.

Edema is common after treatment, especially around the periorbital region, temple, and forehead. Treated tumors usually exude necrotic material, after which an eschar forms and persists for about 4 weeks. Atrophy and hypertrophic scarring have been reported, as have instances of motor and sensory neuropathy.

Evidence (cryosurgery):

As noted in the Radiation therapy section, a small 93-patient trial compared cryosurgery with radiation therapy, with only 1 year of follow-up.[24][Level of evidence B3]

Sources: Radiation therapy · 24 · Level of evidence B3

As noted in the Radiation therapy section, a small 93-patient trial compared cryosurgery with radiation therapy, with only 1 year of follow-up.[24][Level of evidence B3]

There was a statistically significant higher recurrence rate with cryosurgery than with radiation therapy (39% vs. 4%).

In a small, single-center, randomized study, 88 patients were assigned to undergo either cryosurgery in two freeze-thaw cycles; or PDT using delta-aminolevulinic acid as the photosensitizing agent and 635 nm wavelength light with 60 J/cm2 energy delivered by neodymium-doped yttrium aluminum garnet (Nd:YAG) laser.[36][Level of evidence B1]

Sources: 36 · Level of evidence B1

In a small, single-center, randomized study, 88 patients were assigned to undergo either cryosurgery in two freeze-thaw cycles; or PDT using delta-aminolevulinic acid as the photosensitizing agent and 635 nm wavelength light with 60 J/cm2 energy delivered by neodymium-doped yttrium aluminum garnet (Nd:YAG) laser.[36][Level of evidence B1]

Overall clinical efficacy was similar in evaluable lesions at 1 year (5 of 39 recurrences for cryosurgery vs. 2 of 44 recurrences for PDT), but more re-treatments were needed with PDT to achieve complete responses.[36][Level of evidence B1]

Sources: 36 · Level of evidence B1

Cosmetic outcomes favored PDT (93% good or excellent after PDT vs. 54% after cryosurgery, P < .001).

In another randomized study of 118 patients, reported in abstract form, cryosurgery was compared with PDT using methyl aminolevulinic acid.[37,38][Level of evidence B3]

Sources: 37 · 38 · Level of evidence B3

In another randomized study of 118 patients, reported in abstract form, cryosurgery was compared with PDT using methyl aminolevulinic acid.[37,38][Level of evidence B3]

Tumor control rates at 3 years were similar (74%), but cosmetic outcomes were better in the PDT group. These cryosurgery-PDT comparisons were reported on a per-protocol basis rather than an intent-to-treat basis.[37,38][Level of evidence B3]

Sources: 37 · 38 · Level of evidence B3

Health professional · Treatment of Basal Cell Carcinoma of the Skin / Treatment of Basal Cell Carcinoma of the Skin (Localized Disease)

Photodynamic therapy

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

PDT with photosensitizers is used in the management of a wide spectrum of superficial epithelial tumors.[39] A topical photosensitizing agent such as 5-aminolevulinic acid or methyl aminolevulinate is applied to the tumor, followed by exposure to a specific wavelength of light (laser or broad band), depending on the absorption characteristics of the photosensitizer. In the case of multiple BCCs, the use of short-acting systemic (intravenous) photosensitizers such as verteporfin has been investigated.[40] Upon light activation, the photosensitizer reacts with oxygen in the tissue to form singlet oxygen species, resulting in local cell destruction.

Sources: 39 · 40

Evidence (PDT):

In case series, PDT has been associated with high initial CR rates. However, substantial regrowth rates of up to 50% have been reported with long-term follow-up.[39]

Sources: 39

A randomized trial of PDT versus excision is described in the Surgical excision with margin evaluation section.[16]

Sources: Surgical excision with margin evaluation · 16

Two small trials, one reported in abstract form, comparing PDT with cryosurgery are summarized in the Cryosurgery section, showing similar antitumor efficacy but better cosmesis with PDT.[36-38]

Sources: Cryosurgery · 36 · 38

Health professional · Treatment of Basal Cell Carcinoma of the Skin / Treatment of Basal Cell Carcinoma of the Skin (Localized Disease)

Topical fluorouracil (5-FU)

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Topical 5-FU, as a 5% cream, may be useful in specific limited circumstances. The U.S. Food and Drug Administration (FDA) approved this treatment for superficial BCCs in patients for whom conventional methods are impractical, such as individuals with multiple lesions or difficult treatment sites. Safety and efficacy in other indications have not been established.[41,42][Level of evidence C3] Given the superficial nature of the effects of topical 5-FU, nonvisible dermal involvement may persist, giving a false impression of treatment success. In addition, the brisk accompanying inflammatory reaction may cause substantial skin toxicity and discomfort in a large proportion of patients.

Sources: 41 · 42 · Level of evidence C3

Health professional · Treatment of Basal Cell Carcinoma of the Skin / Treatment of Basal Cell Carcinoma of the Skin (Localized Disease)

Imiquimod topical therapy

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Imiquimod is an agonist for the toll-like receptor 7 and/or 8, inducing a helper T-cell cytokine cascade and interferon production. It purportedly acts as an immunomodulator.

Although the FDA approved imiquimod for treatment of superficial BCCs, some investigators in the field do not recommend it for initial monotherapy for BCC. Some reserve its use for patients with small lesions in low-risk sites who cannot undergo treatment with more established therapies.[42] Imiquimod is available as a 5% cream and is used in schedules ranging from twice weekly to twice daily over 5 to 15 weeks. Most of the experience is limited to case series of BCCs that are smaller than 2 cm2 in area and that are not in high-risk locations (e.g., within 1 cm of the hairline, eyes, nose, mouth, or ear; or in the anogenital, hand, or foot regions).[42] Follow-up times have also been generally short. Reported CR rates vary widely, from about 40% to 100%.[42][Level of evidence C3]

Sources: 42 · 42 · 42 · Level of evidence C3

There have been a number of randomized trials of imiquimod.[43-48] However, the designs of all of them make interpretation of long-term efficacy impossible. Most were industry-sponsored dose-finding studies, with small numbers of patients on any given regimen. In addition, patients were only monitored for 6 to 12 weeks, with excision at that time to determine histological response.[42][Level of evidence B3]

Sources: 43 · 48 · 42 · Level of evidence B3

Health professional · Treatment of Basal Cell Carcinoma of the Skin / Treatment of Basal Cell Carcinoma of the Skin (Localized Disease)

Carbon dioxide laser

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

The carbon dioxide laser is used very infrequently in the management of BCC because of the difficulty in controlling tumor margins.[49] Few clinicians have extensive experience with the technique for BCC treatment. There are no randomized trials comparing it with other modalities.

Sources: 49

Health professional · Treatment of Basal Cell Carcinoma of the Skin

Treatment of Metastatic Basal Cell Carcinoma (or Locally Advanced Disease Untreatable by Local Modalities)

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Treatment options for metastatic BCC of the skin (or locally advanced disease untreatable by local modalities) include:

Hedgehog pathway inhibitors.

Sources: Hedgehog pathway inhibitors

Hedgehog pathway inhibitors.

Vismodegib.

Sonidegib.

Chemotherapy.

Sources: Chemotherapy

Health professional · Treatment of Basal Cell Carcinoma of the Skin / Treatment of Metastatic Basal Cell Carcinoma (or Locally Advanced Disease Untreatable by Local Modalities)

Hedgehog pathway inhibitors

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

BCCs frequently exhibit constitutive activation of the Hedgehog/PTCH1 signaling pathway. Vismodegib and sonidegib, two inhibitors of Smoothened, a transmembrane protein involved in the Hedgehog pathway, are approved for the treatment of adults with metastatic BCC, patients with locally advanced BCC that has recurred after surgery, and patients who are not candidates for surgery or radiation therapy.

Evidence (vismodegib):

FDA approval was supported by an international, multicenter, open-label, two-cohort trial enrolling 104 patients: 33 with metastatic BCC and 71 with locally advanced BCC with inoperable disease or for whom surgery was inappropriate. Patients received vismodegib 150 mg daily.[50][Level of evidence C3] Objective response rate (RR) assessed by an independent review committee was the primary end point. The study was sized to test whether the RR was higher than 10% in patients with metastatic BCC and higher than 20% in patients with locally advanced BCC by exact binomial 1-sided tests. Of the 104 patients, 96 were evaluable for RR, with 8 patients who had locally advanced BCC excluded from analysis after the independent pathologist did not identify BCC in the biopsy specimens. In both cohorts, the median duration of treatment was 10.2 months (range, 0.7–18.7 months).

Sources: 50 · Level of evidence C3

FDA approval was supported by an international, multicenter, open-label, two-cohort trial enrolling 104 patients: 33 with metastatic BCC and 71 with locally advanced BCC with inoperable disease or for whom surgery was inappropriate. Patients received vismodegib 150 mg daily.[50][Level of evidence C3] Objective response rate (RR) assessed by an independent review committee was the primary end point. The study was sized to test whether the RR was higher than 10% in patients with metastatic BCC and higher than 20% in patients with locally advanced BCC by exact binomial 1-sided tests. Of the 104 patients, 96 were evaluable for RR, with 8 patients who had locally advanced BCC excluded from analysis after the independent pathologist did not identify BCC in the biopsy specimens. In both cohorts, the median duration of treatment was 10.2 months (range, 0.7–18.7 months).

In 33 patients with metastatic BCC, the RR was 30% (95% CI, 16%–48%; P = .001). In 63 patients with locally advanced BCC, the RR was 43% (95% CI, 31%–56%; P < .001), with complete responses in 13 patients (21%). In both cohorts, the median duration of response was 7.6 months.[50][Level of evidence C3]

Sources: 50 · Level of evidence C3

The most common adverse events were muscle spasms, alopecia, dysgeusia, weight loss, and fatigue. Adverse events led to the discontinuation of vismodegib in 12% of patients.

There were fatal adverse events in seven patients: three deaths from unknown causes; and one death each from hypovolemic shock, myocardial infarction, meningeal disease, and ischemic stroke. The relationship between the study drug and the deaths is unknown.

Evidence (sonidegib):

Sonidegib was evaluated at two doses in a multinational, double-blind, multiple-cohort trial conducted in patients with metastatic BCC (n = 36) or locally advanced BCC (n = 194).[51]Level of evidence B3] Patients were randomly assigned (in a 2:1 fashion) to receive either 200 mg or 800 mg orally, once a day. The primary end point was RR, with data collected up to 6 months after randomization of the last patient and determined by blinded central review. A sample size of 210 patients was targeted to ensure 150 patients for the primary efficacy analysis, which required locally advanced disease to be assessable by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Success was prespecified as a 30% RR.

Sources: 51 · Level of evidence B3

Sonidegib was evaluated at two doses in a multinational, double-blind, multiple-cohort trial conducted in patients with metastatic BCC (n = 36) or locally advanced BCC (n = 194).[51]Level of evidence B3] Patients were randomly assigned (in a 2:1 fashion) to receive either 200 mg or 800 mg orally, once a day. The primary end point was RR, with data collected up to 6 months after randomization of the last patient and determined by blinded central review. A sample size of 210 patients was targeted to ensure 150 patients for the primary efficacy analysis, which required locally advanced disease to be assessable by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Success was prespecified as a 30% RR.

In the 200-mg cohort, a central review identified 18 of 42 patients with locally advanced BCC (43%; 95% CI, 28%–59%) and 2 of 13 patients with metastatic BCC (15%; 95% CI, 2%–45%) who had an objective response and qualified for the primary efficacy analysis. The median duration of response was not reached. RR was similar in the two-dose cohorts, with fewer adverse events at the lower dose, leading to FDA approval of the 200-mg once-daily dose.[51][Level of evidence B3]

Sources: 51 · Level of evidence B3

Frequent adverse events included muscle spasms, alopecia, dysgeusia, fatigue, nausea, vomiting, decreased appetite, decreased weight, myalgia, and pain.

Four patients in the 800-mg cohort died during the study: two from cardiac death and two from metastatic disease progression.

Health professional · Treatment of Basal Cell Carcinoma of the Skin / Treatment of Metastatic Basal Cell Carcinoma (or Locally Advanced Disease Untreatable by Local Modalities)

Chemotherapy

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

No standard chemotherapy regimens exist, and there are only anecdotal reports in the literature.[52]

Sources: 52

Because there is no curative therapy for metastatic BCC of the skin, clinical trials are appropriate. Information about ongoing clinical trials is available from the NCI website.

Sources: NCI website

Health professional · Treatment of Basal Cell Carcinoma of the Skin

Treatment of Recurrent Nonmetastatic Basal Cell Carcinoma of the Skin

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

After treatment of BCC, patients are monitored clinically and examined regularly. Most recurrences occur within 5 years, but about 18% of recurrences are diagnosed beyond that point.[11]

Sources: 11

Patients who develop a primary BCCs are also at increased risk of subsequent primary skin cancers because their sun-damaged skin is susceptible to additional cancers.[53-55] This effect is sometimes termed field carcinogenesis. Age at diagnosis of the first BCC (<65 years), red hair, and initial BCC on the upper extremities appear to be associated with a higher risk of subsequent new BCCs.[56]

Sources: 53 · 55 · 56

Treatment options for recurrent nonmetastatic BCC of the skin include:

Surgical excision.

Mohs micrographic surgery.

Mohs micrographic surgery is commonly used for local recurrences of BCC.

Evidence (surgical excision vs. Mohs micrographic surgery):

In a separate group within a randomized trial that compared excision with Mohs micrographic surgery for primary BCCs, 204 patients with recurrent BCCs were randomly assigned to undergo either excision or Mohs micrographic surgery.[12][Level of evidence B1]

Sources: 12 · Level of evidence B1

In a separate group within a randomized trial that compared excision with Mohs micrographic surgery for primary BCCs, 204 patients with recurrent BCCs were randomly assigned to undergo either excision or Mohs micrographic surgery.[12][Level of evidence B1]

The recurrence rates were 8 of 102 patients assigned to excision and 2 of 102 patients assigned to Mohs micrographic surgery, after a mean follow-up of 2.08 years (P = NS).[12][Level of evidence B1]

Sources: 12 · Level of evidence B1

There were more postoperative complications—including wound infections, graft necrosis, or bleeding—in the excision group than in the Mohs surgery group (19% vs. 8%, P = .021).

As with primary tumors, the operative costs associated with Mohs surgery were higher than those associated with excision (489.06 Euros vs. 323.49 Euros; P = .001).

Health professional

Treatment of Squamous Cell Carcinoma of the Skin

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Localized squamous cell carcinoma (SCC) of the skin is a highly curable disease.[1] There are a variety of treatment approaches to localized SCC, including excision, radiation therapy, cryosurgery, and electrodesiccation and curettage.

Sources: 1

There is little to no good-quality evidence that allows direct comparison of outcomes for patients with sporadic, clinically localized SCCs treated with local therapies. A systematic literature review found only one randomized controlled trial in the management of such patients, and that trial compared adjuvant therapy with observation after initial local therapy rather than different local therapies.[2] In that small single-center trial, 66 patients with high-risk, clinically localized SCC were randomly assigned, after surgical excision of the primary tumor (with or without radiation, depending on clinical judgment), to either receive combined isotretinoin (1 mg/kg orally per day) plus interferon alfa (3 × 106 U subcutaneously 3 times/week) for 6 months or undergo observation.[3] In the 65 evaluable patients after a median follow-up of 21.5 months, there was no difference in the combined (primary) end point of SCC recurrence or second primary tumor (45% vs. 38%; hazard ratio, 1.13; 95% confidence interval [CI], 0.53–2.41), or in either of the individual components of the primary end point.[3][Level of evidence B1]

Sources: 2 · 3 · 3 · Level of evidence B1

Cemiplimab and pembrolizumab, programmed death receptor-1 (PD-1) inhibitors, are the only systemic therapies for the treatment of locally advanced and metastatic cutaneous SCC. The U.S. Food and Drug Administration (FDA) approved cemiplimab and pembrolizumab based on objective response rates (RRs) from early-phase trials.[4-6][Level of evidence C3] Toxicities associated with checkpoint inhibitors were seen, including death. Clinical trials are recommended to further identify optimal treatment. Ongoing trials include PD-1 inhibitors in the neoadjuvant, adjuvant, and advanced/metastatic settings, as monotherapy and in combinations.

Sources: 4 · 6 · Level of evidence C3

Health professional · Treatment of Squamous Cell Carcinoma of the Skin

Treatment of Squamous Cell Carcinoma of the Skin (Localized Disease)

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Treatment options for SCC of the skin (localized disease) include:

Surgical excision with margin evaluation.

Sources: Surgical excision with margin evaluation

Mohs micrographic surgery.

Sources: Mohs micrographic surgery

Radiation therapy.

Sources: Radiation therapy

Curettage and electrodesiccation.

Sources: Curettage and electrodesiccation

Cryosurgery.

Sources: Cryosurgery

Health professional · Treatment of Squamous Cell Carcinoma of the Skin / Treatment of Squamous Cell Carcinoma of the Skin (Localized Disease)

Surgical excision with margin evaluation

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Excision is probably the most common therapy for SCC.[7] This traditional surgical treatment usually relies on surgical margins ranging from 4 mm to 10 mm, depending on the diameter of the tumor and degree of differentiation. In a prospective case series of 141 SCCs, a 4-mm margin was adequate to encompass all subclinical microscopic tumor extension in more than 95% of well-differentiated tumors up to 19 mm in diameter. Wider margins of 6 mm to 10 mm were needed for larger or less-differentiated tumors and tumors in high-risk locations (e.g., scalp, ears, eyelids, nose, and lips).[8] Re-excision may be required if the surgical margin is inadequate on permanent sectioning.

Sources: 7 · 8

Health professional · Treatment of Squamous Cell Carcinoma of the Skin / Treatment of Squamous Cell Carcinoma of the Skin (Localized Disease)

Mohs micrographic surgery

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Mohs micrographic surgery is a form of tumor excision that involves progressive radial sectioning and real-time examination of the resection margins until adequate uninvolved margins have been achieved, avoiding wider margins than needed. It is a specialized technique used to achieve the narrowest margins necessary to avoid tumor recurrence while maximally preserving cosmesis. The tumor is microscopically delineated, with serial radial resection, until it is completely removed as assessed with real-time frozen sections. However, because the technique removes tumor growing in contiguity and may miss noncontiguous in-transit cutaneous micrometastases, some practitioners remove an additional margin of skin in high-risk lesions, even after the Mohs surgical procedure confirms uninvolved margins.[7][Level of evidence C3] In case series, Mohs surgery has been associated with a lower local recurrence rate than the other local modalities,[9] but there are no randomized trials allowing direct comparison.[2]

Sources: 7 · Level of evidence C3 · 9 · 2

This surgery is best suited to the management of tumors in cosmetically sensitive areas (e.g., eyelid periorbital area, nasolabial fold, nose-cheek angle, posterior cheek sulcus, pinna, ear canal, forehead, scalp, fingers, and genitalia) or for tumors that have recurred after initial excision.[10,11] Mohs micrographic surgery is also used to treat high-risk tumors with poorly defined clinical borders or with perineural invasion.

Sources: 10 · 11

Health professional · Treatment of Squamous Cell Carcinoma of the Skin / Treatment of Squamous Cell Carcinoma of the Skin (Localized Disease)

Radiation therapy

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Radiation therapy is a logical treatment choice, particularly for patients with primary lesions requiring difficult or extensive surgery (e.g., lesions on the nose, lips, or ears).[7,12] Radiation therapy eliminates the need for skin grafting in cases where surgery would result in an extensive defect. Cosmetic results are generally good, with a small amount of hypopigmentation or telangiectasia in the treatment port. Radiation therapy can also be used for lesions that recur after a primary surgical approach.[13]

Sources: 7 · 12 · 13

Radiation therapy is avoided in patients with conditions that predispose them to radiation-induced cancers, such as xeroderma pigmentosum or basal cell nevus syndrome.

Although radiation therapy, with or without excision of the primary tumor, is used for histologically proven clinical lymph node metastases and has been associated with favorable disease-free survival rates, the retrospective nature of these case series makes it difficult to know the impact of nodal radiation on survival.[14,15][Level of evidence C2]

Sources: 14 · 15 · Level of evidence C2

Health professional · Treatment of Squamous Cell Carcinoma of the Skin / Treatment of Squamous Cell Carcinoma of the Skin (Localized Disease)

Curettage and electrodesiccation

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Curettage and electrodesiccation is used to treat SCC of the skin. A sharp curette is used to scrape the tumor down to its base, followed by electrodesiccation of the lesion base. Although curettage and electrodesiccation is a quick method for destroying the tumor, the adequacy of treatment cannot be assessed immediately because the surgeon cannot visually detect the depth of microscopic tumor invasion. Its use is limited to small (<1 cm), well-defined, and well-differentiated tumors.[7][Level of evidence C2] This procedure is also sometimes called electrosurgery.

Sources: 7 · Level of evidence C2

Health professional · Treatment of Squamous Cell Carcinoma of the Skin / Treatment of Squamous Cell Carcinoma of the Skin (Localized Disease)

Cryosurgery

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Cryosurgery may be considered for patients with small, clinically well-defined primary tumors. It may be useful for patients with medical conditions that preclude other types of surgery.[16,17] Contraindications for cryosurgery include:

Sources: 16 · 17

Abnormal cold tolerance.

Cryoglobulinemia or cryofibrinogenemia.

Raynaud disease (in the case of lesions on the hands and feet).

Platelet deficiency disorders.

Tumors of the scalp, ala nasi, nasolabial fold, tragus, postauricular sulcus, free eyelid margin, upper lip vermillion border, and lower legs.

Tumors near nerves.

Caution should also be used before treating nodular ulcerative neoplasia larger than 3 cm in diameter, carcinomas fixed to the underlying bone or cartilage, tumors situated on the lateral margins of the fingers and at the ulnar fossa of the elbow, or recurrent carcinomas following surgical excision. Permanent pigment loss at the treatment site is unavoidable, so the treatment is not well suited to patients with dark skin.

Edema is common after treatment, especially around the periorbital region, temple, and forehead. Treated tumors usually exude necrotic material, after which an eschar forms and persists for about 4 weeks. Atrophy and hypertrophic scarring have been reported, as have instances of motor and sensory neuropathy.

Health professional · Treatment of Squamous Cell Carcinoma of the Skin / Treatment of Squamous Cell Carcinoma of the Skin (Localized Disease)

Treatment of SCC in situ (Bowen disease)

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

The management of SCC in situ (Bowen disease) is similar to that for good-risk SCC. However, because Bowen disease is noninvasive, surgical excision, including Mohs micrographic surgery, is usually not necessary. In addition, high complete response (CR) rates are achievable with photodynamic therapy (PDT).

Evidence (PDT):

In a multicenter trial, 229 patients (209 evaluated in a per-protocol/per-lesion analysis) were randomly assigned to receive PDT (methyl aminolevulinate + 570–670 nm red light; n = 91); placebo cream with red light (n = 15); or treatment by physician choice (cryotherapy, n = 77; topical fluorouracil [5-FU], n = 26).[18][Level of evidence B1]

Sources: 18 · Level of evidence B1

In a multicenter trial, 229 patients (209 evaluated in a per-protocol/per-lesion analysis) were randomly assigned to receive PDT (methyl aminolevulinate + 570–670 nm red light; n = 91); placebo cream with red light (n = 15); or treatment by physician choice (cryotherapy, n = 77; topical fluorouracil [5-FU], n = 26).[18][Level of evidence B1]

The sustained complete clinical RRs at 12 months were 80% for PDT, 67% for placebo cream with red light, and 69% for treatment of physician choice (P = .04 for the comparison between PDT and the two combined physician-choice groups).[18][Level of evidence B1]

Sources: 18 · Level of evidence B1

The cosmetic results were best in the PDT group. (For comparison, the CR rates at 3 months were 93% for PDT and 21% for placebo/PDT.)

Health professional · Treatment of Squamous Cell Carcinoma of the Skin

Treatment of Metastatic Squamous Cell Carcinoma (or Advanced Disease Untreatable by Local Modalities)

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

As is the case with basal cell carcinoma (BCC), metastatic and far-advanced SCC is unusual, and reports of systemic therapy are limited to case reports, small case series, or early-phase trials with tumor response as the end point.[Level of evidence C3] The metastatic rates are 5% for primary tumors of sun-exposed skin, 9% for tumors of the external ear, and 14% for tumors of the lip. Metastases occur at an even higher rate (about 38%) for primary SCCs in scar carcinomas or in nonexposed areas of skin.[9] About 69% of metastases are diagnosed within 1 year, 91% within 3 years, and 96% within 5 years.

Sources: Level of evidence C3 · 9

Health professional · Treatment of Squamous Cell Carcinoma of the Skin / Treatment of Metastatic Squamous Cell Carcinoma (or Advanced Disease Untreatable by Local Modalities)

Immunotherapy (PD-1 inhibitors)

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Two PD-1 inhibitors, cemiplimab and pembrolizumab, have been approved by the FDA as systemic therapy for recurrent or metastatic SCC not amenable to curative surgery or radiation therapy (cemiplimab, pembrolizumab) and locally advanced SCC not amenable to curative surgery (cemiplimab).

Health professional · Treatment of Squamous Cell Carcinoma of the Skin / Treatment of Metastatic Squamous Cell Carcinoma (or Advanced Disease Untreatable by Local Modalities) / Immunotherapy (PD-1 inhibitors)

Cemiplimab

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

The FDA approved cemiplimab for systemic therapy for metastatic or locally advanced SCC not amenable to curative surgery or radiation therapy. Approval was based on RR as assessed by an independent review committee in two open-label, multicenter, early-phase trials.[4,5][Level of evidence C3] The FDA-approved dose is a fixed-dose equivalent (350 mg as a 30-minute intravenous [IV] infusion administered every 3 weeks) of the trial dose given as 3 mg/kg IV over 30 minutes every 2 weeks. Toxicities associated with checkpoint inhibitors were seen, including death.

Sources: 4 · 5 · Level of evidence C3

Evidence (cemiplimab):

A phase I expansion cohort trial (NCT02383212) that required patients to have at least one measurable lesion enrolled patients with metastatic (n = 16) or locally advanced (n = 10) SCC. Cemiplimab was administered as 3 mg/kg IV over 30 minutes every 2 weeks.[4]

Sources: NCT02383212 · 4

A phase I expansion cohort trial (NCT02383212) that required patients to have at least one measurable lesion enrolled patients with metastatic (n = 16) or locally advanced (n = 10) SCC. Cemiplimab was administered as 3 mg/kg IV over 30 minutes every 2 weeks.[4]

Formal hypothesis testing was not included in phase I. However, responses, as assessed by an independent review committee, were seen in 13 of 26 patients using Response Evaluation Criteria In Solid Tumors (RECIST) criteria for radiological scans.[4]

Sources: 4

A phase II trial (NCT02760498) entered patients into one of two cohorts: patients with metastatic SCC (nodal or distant; 59 patients) [4] or patients with locally advanced SCC who were not eligible for local surgery or radiation therapy (78 patients).[5]Patients were required to have at least one measurable lesion and were excluded for an autoimmune disease that required systemic therapy within 5 years, previous checkpoint inhibitor therapy, solid organ transplant, Eastern Cooperative Oncology Group performance status below 1, and hepatitis or infection with HIV. Patients received treatment with 3 mg/kg IV every 2 weeks until progressive disease. RRs were assessed by an independent review committee using RECIST criteria for radiological scans and World Health Organization criteria for medical photography for a composite response. RRs were assessed after all patients had at least 6 months of follow-up.

Sources: NCT02760498 · 4 · 5

A phase II trial (NCT02760498) entered patients into one of two cohorts: patients with metastatic SCC (nodal or distant; 59 patients) [4] or patients with locally advanced SCC who were not eligible for local surgery or radiation therapy (78 patients).[5]Patients were required to have at least one measurable lesion and were excluded for an autoimmune disease that required systemic therapy within 5 years, previous checkpoint inhibitor therapy, solid organ transplant, Eastern Cooperative Oncology Group performance status below 1, and hepatitis or infection with HIV. Patients received treatment with 3 mg/kg IV every 2 weeks until progressive disease. RRs were assessed by an independent review committee using RECIST criteria for radiological scans and World Health Organization criteria for medical photography for a composite response. RRs were assessed after all patients had at least 6 months of follow-up.

Metastatic disease: Twenty-eight of 59 patients had a response (47%; 95% CI, 34%−61%); 4 patients (7%) had a CR. The median duration of follow-up was 7.9 months with median duration of response not reached. When results from the 16 patients with metastatic disease in the phase I study were pooled with the results from the 59 patients with metastatic disease in the phase II cohort, the RR in 75 patients remained 47% (95% CI, 35%−59%).

Locally advanced disease: A total of 78 patients with locally advanced disease (i.e., no nodal metastases) were enrolled in the phase II cohort. The RR was 44% (34 patients; 95% CI, 32−55), with CRs reported in 10 patients (13%). The median duration of follow-up was 9.3 months at the time of data cut-off, with a median duration of response not reached.

Exploratory immunohistochemistry analysis did not show predictive value of baseline PD-L1.

Adverse events were consistent with PD-1 inhibitors. In the phase II trial, approximately 7% to 8% of patients discontinued treatment because of adverse events, and there were five treatment-emergent adverse events leading to death.

Health professional · Treatment of Squamous Cell Carcinoma of the Skin / Treatment of Metastatic Squamous Cell Carcinoma (or Advanced Disease Untreatable by Local Modalities) / Immunotherapy (PD-1 inhibitors)

Pembrolizumab

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Pembrolizumab is approved for systemic therapy for recurrent or metastatic SCC not amenable to surgery or radiation therapy. Approval was based on RR as assessed by an independent review committee of a multicenter, multicohort, open-label phase II trial in patients with recurrent or metastatic SCC not amenable to surgery or radiation therapy.[6][Level of evidence C3] The cohort of patients with locally advanced disease is not yet reported. Patients received pembrolizumab 200 mg every 3 weeks. An alternate dosing regimen of pembrolizumab, 400 mg every 6 weeks, is approved across all adult indications based on pharmacokinetic modeling and exposure-response analyses.

Sources: 6 · Level of evidence C3

Evidence (pembrolizumab):

A single-arm phase II trial (KEYNOTE-629 [NCT03284424]) enrolled 105 patients into the cohort of recurrent or metastatic SCC.[6] Patients were required to have measurable disease and were excluded for an autoimmune disease or a medical condition requiring immunosuppression or an Eastern Cooperative Oncology Group Performance Status above grade 1. Treatment continued for up to 2 years in the absence of disease progression, unacceptable toxicity, or investigator or patient decision to withdraw. If stable, patients with radiological-only evidence of progressive disease at first assessment were permitted to continue treatment until progressive disease was confirmed. The primary end point was RR per RECIST v1.1.

Sources: KEYNOTE-629 · 6

A single-arm phase II trial (KEYNOTE-629 [NCT03284424]) enrolled 105 patients into the cohort of recurrent or metastatic SCC.[6] Patients were required to have measurable disease and were excluded for an autoimmune disease or a medical condition requiring immunosuppression or an Eastern Cooperative Oncology Group Performance Status above grade 1. Treatment continued for up to 2 years in the absence of disease progression, unacceptable toxicity, or investigator or patient decision to withdraw. If stable, patients with radiological-only evidence of progressive disease at first assessment were permitted to continue treatment until progressive disease was confirmed. The primary end point was RR per RECIST v1.1.

An interim analysis at 11 months of follow-up (range, 0.4−16.3 months) demonstrated an RR of 34% (95% CI, 25%−44%) with four CRs. Median duration of response has not been reached (range, 3−13± months).

Exploratory analysis of programmed death ligand 1 combined positive score by immunohistochemistry did not predict response to treatment.

Adverse events were consistent with PD-1 inhibitors. Treatment-emergent adverse events led to discontinuation in 13 patients (12%); five (5%) were considered treatment-emergent adverse events, including pneumonitis, cranial nerve neuropathy, and renal failure. Grade 5 treatment-emergent adverse events occurred in 12 patients (11%) and included infection, cardiac failure, and respiratory failure. One death from cranial nerve neuropathy was considered treatment related.

As treatment options and long-term outcomes are limited, clinical trials are recommended. Trial options include PD-1 inhibitors and cemiplimab in the advanced setting, as well as in the neoadjuvant and adjuvant settings; other checkpoint inhibitors; checkpoint inhibitor combinations; and combinations with epidermal growth factor receptor inhibitors.

Health professional · Treatment of Squamous Cell Carcinoma of the Skin

Treatment of Recurrent Nonmetastatic Squamous Cell Carcinoma of the Skin

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

SCCs have definite metastatic potential, and patients are monitored regularly after initial treatment. Overall, local recurrence rates after treatment of primary SCCs have ranged from about 3% to 23%, depending on anatomical site.[9] About 58% of local recurrences manifest within 1 year, 83% within 3 years, and 95% within 5 years. Tumors that are 2 cm or larger in diameter, 4 mm or greater in depth, or poorly differentiated have a relatively poor prognosis [19] and even higher local recurrence and metastasis rates than those listed.[9] Reported local recurrence rates also vary by treatment modality, with the lowest rates associated with Mohs micrographic surgery. However, at least some of the variation may be the result of patient selection factors. No randomized trials directly compare the various local treatment modalities.

Sources: 9 · 19 · 9

Treatment options for recurrent nonmetastatic SCCs include:

Surgical excision.

Mohs micrographic surgery.

Radiation therapy.

Recurrent nonmetastatic SCCs are considered high risk and are generally treated with excision, often using Mohs micrographic surgery. Radiation therapy is used for lesions that cannot be completely resected.

As is the case with BCC, patients who develop a primary SCC are also at increased risk of subsequent primary skin cancers.[20,21]

Sources: 20 · 21

Health professional

Treatment of Actinic Keratosis

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Actinic keratoses commonly appear in areas of chronic sun exposure, such as the face and dorsa of the hands. Actinic cheilitis is a related condition that usually appears on the lower lips.[1] These conditions represent early epithelial transformation that may eventually evolve into invasive squamous cell carcinoma (SCC).

Sources: 1

Actinic keratoses are noninvasive lesions. The progression rate is extremely low. In a prospective study, the progression rate to SCC was less than 1 in 1,000 per year, calling into question the cost-effectiveness of treating all actinic keratoses to prevent SCC.[2] Moreover, in a population-based longitudinal study, there was a spontaneous regression rate of approximately 26% for solar keratoses within 1 year of a screening examination.[3] Therefore, studies designed to test the efficacy of any treatment for progression of actinic keratoses to SCC are impractical (or impossible). Nevertheless, a variety of treatment approaches have been reviewed.[4]

Sources: 2 · 3 · 4

Treatment options for actinic keratosis depend on whether the lesions are isolated or whether there are multiple lesions in the same field.

Treatment options for actinic keratosis (not listed hierarchically) include:

Topical agents.

Topical agents.

Fluorouracil (5-FU).

Imiquimod cream.

Diclofenac sodium 3% gel.

Ingenol mebutate.

Chemical peels.

Chemical peels.

Trichloroacetic acid.

Surgery.

Surgery.

Surgical excision.

Shave excision.

Curettage with or without electrodesiccation.

Dermabrasion.

Photodynamic therapy.

Laser therapy (carbon dioxide or erbium-doped yttrium aluminum garnet [Er:YAG] laser).

For patients · General Information About Skin Cancer

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

The prognosis for squamous cell carcinoma of the skin depends mostly on the following:

Sources: prognosis

Stage of the cancer.

Sources: Stage

Whether the patient is immunosuppressed.

Sources: immunosuppressed

Whether the patient uses tobacco.

Sources: tobacco

The patient's general health.

Treatment options for basal cell carcinoma and squamous cell carcinoma of the skin depend on the following:

The type of cancer.

The stage of the cancer, for squamous cell carcinoma.

The size of the tumor and what part of the body it affects.

Sources: tumor

The patient's general health.

For patients · Stages of Skin Cancer

Treatment depends on the type of skin cancer or other skin condition diagnosed:

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

For patients · Stages of Skin Cancer / Treatment depends on the type of skin cancer or other skin condition diagnosed:

Basal cell carcinoma

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

Basal cell carcinoma is the most common type of skin cancer. It usually occurs on areas of the skin that have been in the sun, most often the nose. Often this cancer appears as a raised bump that looks smooth and pearly. A less common type looks like a scar or it is flat and firm and may be skin-colored, yellow, or waxy. Basal cell carcinoma may spread to tissues around the cancer, but it usually does not spread to other parts of the body.

Sources: Basal cell carcinoma · skin cancer · cancer · tissues

For patients · Stages of Skin Cancer / Treatment depends on the type of skin cancer or other skin condition diagnosed:

Squamous cell carcinoma

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

Squamous cell carcinoma occurs on areas of the skin that have been damaged by the sun, such as the ears, lower lip, and the back of the hands. Squamous cell carcinoma may also appear on areas of the skin that have been sunburned or exposed to chemicals or radiation. Often this cancer looks like a firm red bump. The tumor may feel scaly, bleed, or form a crust. Squamous cell tumors may spread to nearby lymph nodes. Squamous cell carcinoma that has not spread can usually be cured.

Sources: Squamous cell carcinoma · chemicals · radiation · cancer · tumor · lymph nodes · cured

For patients · Stages of Skin Cancer / Treatment depends on the type of skin cancer or other skin condition diagnosed:

Actinic keratosis

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

Actinic keratosis is a skin condition that is not cancer, but sometimes changes into squamous cell carcinoma. One or more lesions may occur in areas that have been exposed to the sun, such as the face, the back of the hands, and the lower lip. It looks like rough, red, pink, or brown scaly patches on the skin that may be flat or raised, or as a cracked and peeling lower lip that is not helped by lip balm or petroleum jelly. Actinic keratosis may disappear without treatment.

Sources: Actinic keratosis · condition · cancer · squamous cell carcinoma · lesions · petroleum jelly

For patients

Treatment Option Overview

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

There are different types of treatment for patients with basal cell carcinoma, squamous cell carcinoma of the skin, and actinic keratosis.

The following types of treatment are used:

The following types of treatment are used:

Surgery

Radiation therapy

Chemotherapy

Photodynamic therapy

Immunotherapy

Targeted therapy

Chemical peel

Other drug therapy

New types of treatment are being tested in clinical trials.

Treatment for skin cancer may cause side effects.

Patients may want to think about taking part in a clinical trial.

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Follow-up tests may be needed.

For patients · Treatment Option Overview

There are different types of treatment for patients with basal cell carcinoma, squamous cell carcinoma of the skin, and actinic keratosis.

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

Different types of treatment are available for patients with basal cell carcinoma, squamous cell carcinoma of the skin, and actinic keratosis. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.

Sources: basal cell carcinoma · squamous cell carcinoma of the skin · actinic keratosis · standard · clinical trials · research study · cancer

For patients · Treatment Option Overview

The following types of treatment are used:

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview / The following types of treatment are used:

Surgery

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

One or more of the following surgical procedures may be used to treat basal cell carcinoma, squamous cell carcinoma of the skin, or actinic keratosis:

Sources: surgical

Simple excision: The tumor, along with some of the normal tissue around it, is cut from the skin.

Sources: excision · tumor · tissue

Mohs micrographic surgery: The tumor is cut from the skin in thin layers. During the procedure, the edges of the tumor and each layer of tumor removed are viewed through a microscope to check for cancer cells. Layers continue to be removed until no more cancer cells are seen. This type of surgery removes as little normal tissue as possible. It is often used to remove skin cancer on the face, fingers, or genitals and skin cancer that does not have a clear border.

Sources: Mohs micrographic surgery · microscope · cells · skin cancer · genitals

Shave excision: The abnormal area is shaved off the surface of the skin with a small blade.

Sources: abnormal

Curettage and electrodesiccation: The tumor is cut from the skin with a curette (a sharp, spoon-shaped tool). A needle-shaped electrode is then used to treat the area with an electric current that stops the bleeding and destroys cancer cells that remain around the edge of the wound. The process may be repeated one to three times during the surgery to remove all of the cancer. This type of treatment is also called electrosurgery.

Sources: Curettage · electrodesiccation · curette · electrode · wound

Cryosurgery: A treatment that uses an instrument to freeze and destroy abnormal tissue, such as carcinoma in situ. This type of treatment is also called cryotherapy.

Sources: Cryosurgery · carcinoma in situ

Laser surgery: A surgical procedure that uses a laser beam (a narrow beam of intense light) as a knife to make bloodless cuts in tissue or to remove a surface lesion such as a tumor.

Sources: Laser surgery · laser · lesion

Dermabrasion: Removal of the top layer of skin using a rotating wheel or small particles to rub away skin cells.

Sources: Dermabrasion

Simple excision, Mohs micrographic surgery, curettage and electrodesiccation, and cryosurgery are used to treat basal cell carcinoma and squamous cell carcinoma of the skin. Laser surgery is rarely used to treat basal cell carcinoma. Simple excision, shave excision, curettage and desiccation, dermabrasion, and laser surgery are used to treat actinic keratosis.

For patients · Treatment Option Overview / The following types of treatment are used:

Radiation therapy

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.

Sources: Radiation therapy · x-rays · radiation · External radiation therapy

External radiation therapy is used to treat basal cell carcinoma and squamous cell carcinoma of the skin.

For patients · Treatment Option Overview / The following types of treatment are used:

Chemotherapy

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

Sources: Chemotherapy · drugs

Chemotherapy for basal cell carcinoma, squamous cell carcinoma of the skin, and actinic keratosis is usually topical (applied to the skin in a cream or lotion). Topical fluorouracil (5-FU) is used to treat basal cell carcinoma.

Sources: topical · fluorouracil

See Drugs Approved for Basal Cell Carcinoma for more information.

Sources: Drugs Approved for Basal Cell Carcinoma

For patients · Treatment Option Overview / The following types of treatment are used:

Photodynamic therapy

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

Photodynamic therapy (PDT) is a cancer treatment that uses a drug and a certain type of light to kill cancer cells. A drug that is not active until it is exposed to light is injected into a vein or put on the skin. The drug collects more in cancer cells than in normal cells. For skin cancer, laser light is shined onto the skin and the drug becomes active and kills the cancer cells. Photodynamic therapy causes little damage to healthy tissue.

Sources: Photodynamic therapy

Photodynamic therapy is also used to treat actinic keratoses.

For patients · Treatment Option Overview / The following types of treatment are used:

Immunotherapy

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

Immunotherapy is a treatment that uses the patient's immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body's natural defenses against cancer.

Sources: Immunotherapy · immune system

There are different types of immunotherapy used to treat skin cancer:

Immune checkpoint inhibitors block proteins called checkpoints that are made by some types of immune system cells, such as T cells, and some cancer cells. PD-1 is a protein on the surface of T cells that helps keep the body's immune responses in check. PD-L1 is a protein found on some types of cancer cells. When PD-1 attaches to PD-L1, it stops the T cell from killing the cancer cell. PD-1 and PD-L1 inhibitors keep PD-1 and PD-L1 proteins from attaching to each other. This allows the T cells to kill cancer cells.

Sources: Immune checkpoint inhibitors · PD-1 · protein · T cells · immune responses · PD-L1

Immune checkpoint inhibitors block proteins called checkpoints that are made by some types of immune system cells, such as T cells, and some cancer cells. PD-1 is a protein on the surface of T cells that helps keep the body's immune responses in check. PD-L1 is a protein found on some types of cancer cells. When PD-1 attaches to PD-L1, it stops the T cell from killing the cancer cell. PD-1 and PD-L1 inhibitors keep PD-1 and PD-L1 proteins from attaching to each other. This allows the T cells to kill cancer cells.

Cemiplimab and pembrolizumab are types of PD-1 inhibitors used to treat squamous cell carcinoma of the skin that is locally advanced or has spread to other parts of the body.

Sources: Cemiplimab · pembrolizumab

Interferon (by injection) may be used to treat squamous cell carcinoma of the skin.

Sources: Interferon · injection

Topical imiquimod therapy is an immune response modifier that may be used to treat some basal cell carcinomas and is applied to the skin as a cream.

Sources: Topical · imiquimod · immune response

See Drugs Approved for Basal Cell Carcinoma for more information.

Sources: Drugs Approved for Basal Cell Carcinoma

For patients · Treatment Option Overview / The following types of treatment are used:

Targeted therapy

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells.

Sources: Targeted therapy

Signal transduction inhibitor therapy: This treatment block signals that are passed from one molecule to another inside a cell. Blocking these signals may kill cancer cells. Vismodegib and sonidegib are signal transduction inhibitors used to treat basal cell carcinoma.

Sources: Signal transduction inhibitor · molecule · Vismodegib · sonidegib

See Drugs Approved for Basal Cell Carcinoma for more information.

Sources: Drugs Approved for Basal Cell Carcinoma

For patients · Treatment Option Overview / The following types of treatment are used:

Chemical peel

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

A chemical peel is a procedure used to improve the way certain skin conditions look. A chemical solution is put on the skin to dissolve the top layers of skin cells. Chemical peels may be used to treat actinic keratosis. This type of treatment is also called chemabrasion and chemexfoliation.

Sources: chemical peel · chemical

For patients · Treatment Option Overview / The following types of treatment are used:

Other drug therapy

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

Retinoids (drugs related to vitamin A) are sometimes used to treat squamous cell carcinoma of the skin. Diclofenac and ingenol are topical drugs used to treat actinic keratosis.

Sources: Retinoids · vitamin A · Diclofenac · ingenol

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

Information about clinical trials is available from the NCI website.

Sources: NCI website

For patients · Treatment Option Overview

Treatment for skin cancer may cause side effects.

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

For information about side effects caused by treatment for cancer, visit our Side Effects page.

Sources: side effects · Side Effects

For patients · Treatment Option Overview

Patients may want to think about taking part in a clinical trial.

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.

Sources: clinical trial · standard treatment

Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.

Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.

For patients · Treatment Option Overview

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.

Sources: side effects

Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trials search · ClinicalTrials.gov

For patients · Treatment Option Overview

Follow-up tests may be needed.

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).

If basal cell carcinoma and squamous cell carcinoma recur (come back), it is usually within 5 years of initial treatment. Talk to your doctor about how often you should have your skin checked for signs of cancer.

Sources: recur · signs

For patients

Treatment of Basal Cell Carcinoma

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of basal cell carcinoma that is localized may include the following:

Sources: basal cell carcinoma · localized

Simple excision.

Sources: excision

Mohs micrographic surgery.

Sources: Mohs micrographic surgery

Radiation therapy.

Sources: Radiation therapy

Curettage and electrodesiccation.

Sources: Curettage · electrodesiccation

Cryosurgery.

Sources: Cryosurgery

Photodynamic therapy.

Sources: Photodynamic therapy

Topical chemotherapy.

Sources: Topical chemotherapy

Topical immunotherapy (imiquimod).

Sources: Topical · immunotherapy · imiquimod

Laser surgery (rarely used).

Sources: Laser surgery

Treatment of basal cell carcinoma that is metastatic or cannot be treated with local therapy may include the following:

Sources: metastatic · local therapy

Targeted therapy with a signal transduction inhibitor (vismodegib or sonidegib).

Sources: Targeted therapy · signal transduction inhibitor · vismodegib · sonidegib

A clinical trial of a new treatment.

Sources: clinical trial

Treatment of recurrent basal cell carcinoma that is not metastatic may include the following:

Sources: recurrent

Simple excision.

Mohs micrographic surgery.

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Squamous Cell Carcinoma of the Skin

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

Treatment of squamous cell carcinoma that is localized may include the following:

Sources: squamous cell carcinoma · localized

Simple excision.

Sources: excision

Mohs micrographic surgery.

Sources: Mohs micrographic surgery

Radiation therapy.

Sources: Radiation therapy

Curettage and electrodesiccation.

Sources: Curettage · electrodesiccation

Cryosurgery.

Sources: Cryosurgery

Photodynamic therapy, for squamous cell carcinoma in situ (stage 0).

Sources: Photodynamic therapy · squamous cell carcinoma in situ

Treatment of squamous cell carcinoma that is metastatic or cannot be treated with local therapy may include the following:

Sources: metastatic · local therapy

Immunotherapy with cemiplimab or pembrolizumab.

Sources: Immunotherapy · cemiplimab · pembrolizumab

A clinical trial of immune checkpoint inhibitor therapy.

Sources: clinical trial · immune checkpoint inhibitor

Treatment of recurrent squamous cell carcinoma that is not metastatic may include the following:

Sources: recurrent

Simple excision.

Mohs micrographic surgery.

Radiation therapy.

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Actinic Keratosis

Source: Skin Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 1, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Actinic keratosis is not cancer but is treated because it may develop into cancer. Treatment of actinic keratosis may include the following:

Sources: Actinic keratosis · cancer

Topical chemotherapy.

Sources: Topical chemotherapy

Topical immunotherapy (imiquimod).

Sources: Topical · immunotherapy · imiquimod

Other drug therapy (diclofenac or ingenol).

Sources: drug therapy · diclofenac · ingenol

Chemical peel.

Sources: Chemical peel

Simple excision.

Sources: excision

Shave excision.

Curettage and electrodesiccation.

Sources: Curettage · electrodesiccation

Dermabrasion.

Sources: Dermabrasion

Photodynamic therapy.

Sources: Photodynamic therapy

Laser surgery.

Sources: Laser surgery

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

Studies

A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma

NCT00833417 · COMPLETED · phase2

Basal Cell Carcinoma

ClinicalTrials.gov record

A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

NCT01327053 · COMPLETED · phase2

Basal Cell Carcinoma

ClinicalTrials.gov record

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

NCT02383212 · COMPLETED · phase1

Advanced Cancer, Advanced Malignancies

ClinicalTrials.gov record

Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

NCT02760498 · COMPLETED · phase2

Advanced Cutaneous Squamous Cell Carcinoma

ClinicalTrials.gov record

Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)

NCT03284424 · COMPLETED · phase2

Squamous Cell Carcinoma

ClinicalTrials.gov record

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

NCT03969004 · ACTIVE NOT RECRUITING · phase3

Cutaneous Squamous Cell Carcinoma

ClinicalTrials.gov record

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

NCT03894618 · COMPLETED · phase1

Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma,...

ClinicalTrials.gov record

Disease and treatment settings

Basal Cell Carcinoma

Disease and treatment setting

Basal Cell Carcinoma

ERIVEDGE: metastatic Basal Cell Carcinoma after prior therapy

Disease and treatment setting

1 INDICATIONS AND USAGE ERIVEDGE is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and...

KEYTRUDA QLEX: metastatic squamous cell carcinoma

Disease and treatment setting

1.17 Cutaneous Squamous Cell Carcinoma KEYTRUDA QLEX is indicated for the treatment of adult patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC that is not curable by surgery or...

KEYTRUDA: metastatic squamous cell carcinoma

Disease and treatment setting

1.19 Cutaneous Squamous Cell Carcinoma KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC that is not curable by surgery or radiation.

Libtayo: metastatic Basal Cell Carcinoma

Disease and treatment setting

Patients with metastatic basal cell carcinoma (mBCC) previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate

localized Skin Cancer

Disease and treatment setting

Treatment of Basal Cell Carcinoma of the Skin (Localized Disease)

metastatic Skin Cancer

Disease and treatment setting

Treatment of Metastatic Basal Cell Carcinoma (or Locally Advanced Disease Untreatable by Local Modalities)

Odomzo: locally advanced Basal Cell Carcinoma after prior therapy

Disease and treatment setting

ODOMZO is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery...

recurrent Skin Cancer

Disease and treatment setting

Treatment of Recurrent Nonmetastatic Basal Cell Carcinoma of the Skin

Skin Cancer

Disease and treatment setting

Skin Cancer

UNLOXCYT: metastatic squamous cell carcinoma

Disease and treatment setting

INDICATIONS AND USAGE UNLOXCYT is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.

UNLOXCYT: metastatic squamous cell carcinoma with PD-L1 stated without a specific alteration

Disease and treatment setting

UNLOXCYT is a programmed death ligand-1 (PD-L1) blocking antibody indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative...

Drug labels

ERIVEDGE

Label date 2024-12-02

ERIVEDGE is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates...

DailyMed label

Fluorouracil

Label date 2021-06-30

INDICATIONS AND USAGE Fluorouracil 5% Topical Cream is recommended for the topical treatment of multiple actinic or solar keratoses. In the 5% strength, it is also useful in the treatment of superficial basal cell carcinomas when...

DailyMed label

Odomzo

Label date 2024-12-31

ODOMZO (sonidegib) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation...

DailyMed label

Renova

Label date 2026-02-24

INDICATIONS AND USAGE (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) RENOVA (tretinoin cream) 0.02% is indicated as an adjunctive agent (see second bullet...

DailyMed label

UNLOXCYT

Label date 2025-12-08

1. INDICATIONS AND USAGE UNLOXCYT is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation....

DailyMed label